Fátima Baltazar

  • Cancer
  • cancer metabolism
  • glycolysis
  • Warburg effect
  • monocarboxylate transporters (MCTs)
  • lactate
  • targeted therapy
  • resistance to therapy
  • drug discovery

Fátima Baltazar (FB) is Associate Professor of Pharmacology at the School of Medicine, University of Minho (Portugal), Principal Investigator at ICVS (Life and Health Sciences Research Institute), Coordinator of the Cancer Biomarkers and Therapeutics (BiTCancer) team and Vice-Director of ICVS. She holds a First degree in Pharmaceutical Sciences by the University of Coimbra (Portugal), PhD in Biological Sciences by the University of Hull (U.K.).
Her main research interests are on cancer glucose metabolism, focusing on the discovery of new prognostic metabolic biomarkers and cancer therapeutic targets (especially monocarboxylate transporters – MCTs), and more recently on drug discovery.
FB is co-author of 140 international peer-reviewed research articles and 12 book chapters, and edited 2 books. She is (co-)inventor of 2 international patent applications (pending), has a h-index of 41 (ISI Web of Science) and about 5,500 citations. She has more that 30 national and international talks as invited speaker.
FB successfully supervised/co-supervised 11 post-doc projects, 15 PhD thesis, 25 Master theses and many undergraduate projects. She has attracted direct competitive funding for ICVS, at national and international levels. She is invited grant evaluator of different international funding agencies. FB was board member of the International Society of Cancer Metabolism (ISCaM, 2019-2023) and founding member of the Portuguese Society for Clinical Nutrition and Metabolism (SPNCM). She is member of the Editorial Board of several international journals, and member of different national and international organizations, including ASPIC (Portuguese Association for Cancer Research), EACR (European Association for Cancer Research) and ISCaM.

Fátima Baltazar

  • Cancer
  • cancer metabolism
  • glycolysis
  • Warburg effect
  • monocarboxylate transporters (MCTs)
  • lactate
  • targeted therapy
  • resistance to therapy
  • drug discovery

Fátima Baltazar (FB) is Associate Professor of Pharmacology at the School of Medicine, University of Minho (Portugal), Principal Investigator at ICVS (Life and Health Sciences Research Institute), Coordinator of the Cancer Biomarkers and Therapeutics (BiTCancer) team and Vice-Director of ICVS. She holds a First degree in Pharmaceutical Sciences by the University of Coimbra (Portugal), PhD in Biological Sciences by the University of Hull (U.K.).
Her main research interests are on cancer glucose metabolism, focusing on the discovery of new prognostic metabolic biomarkers and cancer therapeutic targets (especially monocarboxylate transporters – MCTs), and more recently on drug discovery.
FB is co-author of 140 international peer-reviewed research articles and 12 book chapters, and edited 2 books. She is (co-)inventor of 2 international patent applications (pending), has a h-index of 41 (ISI Web of Science) and about 5,500 citations. She has more that 30 national and international talks as invited speaker.
FB successfully supervised/co-supervised 11 post-doc projects, 15 PhD thesis, 25 Master theses and many undergraduate projects. She has attracted direct competitive funding for ICVS, at national and international levels. She is invited grant evaluator of different international funding agencies. FB was board member of the International Society of Cancer Metabolism (ISCaM, 2019-2023) and founding member of the Portuguese Society for Clinical Nutrition and Metabolism (SPNCM). She is member of the Editorial Board of several international journals, and member of different national and international organizations, including ASPIC (Portuguese Association for Cancer Research), EACR (European Association for Cancer Research) and ISCaM.

Scientific Highlights

Articles
1. Miranda-Gonçalves V, Gonçalves CS, Granja S, Vieira de Castro J, Reis RM, Costa BM, Baltazar F. MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma. Cancers (Basel). 2021 Jul 11;13(14):3468. doi: 10.3390/cancers13143468. IF 6.64
2. Afonso J, Santos L, Longatto-Filho A, and Baltazar F. Competitive glucose metabolism in tumour and immune cells – A target to boost bladder cancer immunotherapy? Nat Rev Urol. 2020 Feb;17(2):77-106. Review. IF 14.43
2. Riera-Domingo C, Audigé A, Granja S, Cheng WC, Ho PC, Baltazar F, Stockmann C, Mazzone M. Immunity, Hypoxia and Metabolism – the ménage à trois of cancer: implications for immunotherapy. Physiol Rev. 2020 Jan 1;100(1):1-102. Review IF 37.31
3. Pontes O, Costa M, Santos F, Sampaio-Marques B, Dias T, Ludovico P, Baltazar F, Proença F. Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment. Eur J Med Chem. 2018 Sep 5;157:101-114. doi: 10.1016/j.ejmech.2018.07.058. Epub 2018 Jul 26. IF 4.83
4. Miranda-Gonçalves V, Bezerra F, Costa-Almeida R, Freitas-Cunha M, Soares R, Martinho O, Reis RM, Pinheiro C, Baltazar F. Monocarboxylate transporter 1 is a key player in glioma-endothelial cell crosstalk. Mol Carcinog. 2017 Dec;56(12):2630-2642. IF 4.85
5. Granja S, Tavares-Valente D, Queirós O, Baltazar F. Value of pH regulators in the diagnosis, prognosis and treatment of cancer. Semin Cancer Biol. 2017 Apr;43:17-34. IF 10.20
6. Pértega-Gomes N, Felisbino S, Massie C, Vizcaíno JR, Coelho R, Sandi C, Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer L. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: A role for Monocarboxylate Transporters as metabolic targets for therapy. J Pathol 2015, 236(4):517-30. IF 7.38
7. Miranda-Gonçalves V, Honavar M, Pinheiro C, Martinho O, Cordeiro M, Bebiano G, Costa P, Reis RM, Baltazar F. Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets, Neuro-Oncology 2013, 15(2):172-88. IF 5.29

Edited Books
1. Prostate Cancer Metabolism, From Biochemistry to Therapeutics (2021). 1st Edition. Eds. Tomas Koltai, Stephan Reshkin, Fatima Baltazar, Larry Fliegel. Elsevier, eBook ISBN: 9780323905510; Paperback ISBN: 9780323905282.

Patents
1. CHROMENE-BASED COMPOUNDS, METHODS AND USES THEREOF; Costa, Marta; Maria Fernanda R. Paiva Proença; Fátima Baltazar; Patrícia Maciel; Olívia Pontes. 2020; International Patent – Ref: WO/2020/261242. Status: pending
2. ANTIMALARIAL AGENT, METHODS AND USES THEREOF; Costa, Marta; Fátima Baltazar; Maria Fernanda Rego Paiva Proença; Pedro Ferreira; Maria Isabel Veiga; Carla Calçada. 2020.; International Patent – Ref: WO/2021/191882. Status: pending

Add Your Heading Text Here

Projects

As Leader

Projects

As Member